Firms begin study on chewable albendazole formulation

Fidson Health Care Plc has partnered with a clinical research organisation, Liddie BE Ltd to conduct a Bioequivalence (BE) study on their chewable formulation of Albendazole tablets.

The partnership is groundbreaking in the advancement of clinical research and the first Bioequivalence study to be conducted in Nigeria. Albendazole is an FDA-approved medication for the treatment of a variety of parasitic worm infections prevalent in Nigeria and many parts of the world.

Both companies said the BE study will be conducted under stringent regulatory guidelines that meet international standards and will compare the pharmacokinetics of the novel Albendazole formulation with the standard reference.

Speaking at the joint press conference to announce this collaboration, Chief Executive Officer, Fidson, Dr Fidelis Ayebae, stated “We are excited to be at the forefront of innovation and leadership in the healthcare industry in Nigeria with this landmark effort.

“This study is a critical step towards the WHO prequalification of our brand of chewable Albendazole tablets. This collaboration being the first BE study in Nigeria and one of the first in Africa is a testament to the success of indigenous efforts and vision we are proud to lead.”

The Managing Director, Liddie BE Ltd, Prof Lara Orafidiya, said: “We are happy to partner with Fidson on this critical study.”

Our expertise in clinical research will ensure that this product meets the required international standards for safety and efficacy. We are committed to contributing to the healthcare landscape in Nigeria through world-class clinical trials and research.”

The study results are expected to provide key data to support the WHO-PQ programme of the product. This initiative attests to both companies’ commitment to advancing healthcare access and improving clinical outcomes in Nigeria and across the continent.